Evidence map›Paper›PMID 39407652›Full record

ReviewMolecules (Basel, Switzerland)2024

Research Progress on the Mechanisms of Protocatechuic Acid in the Treatment of Cognitive Impairment.

Shuzhi Liang, Zhongmin Zhao, Leilei Liu, Yan Zhang, Xijian Liu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Plants (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuzhi LiangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Zhongmin ZhaoCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Leilei LiuCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.
Yan ZhangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.ORCID 0000-0003-2141-3114
Xijian LiuCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China.

Funding

National Natural Science Foundation of China 82374330
6 · The paper itself

Abstract

Cognitive impairment (CI) is a type of mental health disorder that mainly affects cognitive abilities, such as learning, memory, perception, and problem-solving. Currently, in clinical practice, the treatment of cognitive impairment mainly focuses on the application of cholinesterase inhibitors and NMDA receptor antagonists; however, there is no specific and effective drug yet. Procatechuic acid (PCA) possesses various functions, including antibacterial, antiasthmatic, and expectorant effects. In recent years, it has received growing attention in the cognitive domain. Therefore, by summarizing the mechanisms of action of procatechuic acid in the treatment of cognitive impairment in this paper, it is found that procatechuic acid has multiple effects, such as regulating the expression of neuroprotective factors, inhibiting cell apoptosis, promoting the autophagy-lysosome pathway, suppressing oxidative stress damage, inhibiting inflammatory responses, improving synaptic plasticity dysfunction, inhibiting Aβ deposition, reducing APP hydrolysis, enhancing the cholinergic system, and inhibiting the excitotoxicity of neuronal cells. The involved signaling pathways include activating Pi3K-akt-mTor and inhibiting JNK, P38 MAPK, P38-ERK-JNK, SIRT1, and NF-κB/p53, etc. This paper aims to present the latest progress in research on procatechuic acid, including aspects such as its chemical properties, sources, pharmacokinetics, mechanisms for treating neurodegenerative diseases.

Indexed as

Cognitive DysfunctionHydroxybenzoatesAnimalsHumansNeuroprotective AgentsOxidative StressSignal TransductionHydroxybenzoatesNeuroprotective Agentsprotocatechuic acidcognitive impairmentmechanism of actionprocatechuic acid

Identifiers

PMID39407652
PMCPMC11478363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.